2025 Department of Medicine Grand Rounds | Antimicrobial Stewardship and Current Status of Antimicrobial Prophylaxis in Patients with Hematologic Malignancies and Hematopoietic Cell Transplantation
Antibacterial prophylaxis in neutropenic patients is controversial in both hematologic malignancies and hematopoietic cell transplant recipients. Our institutional SOP provides guidance, however, many providers don’t follow those due to practices at their prior institutions. Ideally, prophylaxis should be directed to those patients that are at highest risk, e.g., those with severe mucositis, however, often times it is used in situations where it is not required.
Frontline health care providers are likely not up-to-date with antimicrobial prophylaxis, and this coupled with variance of practices amongst health care providers leads to currently flawed state. As a result, it is imperative that clinicians are provided with up-to-date evidence on the risks and benefits of antimicrobial prophylaxis and stay up to date on the role of antimicrobial stewardship in patients with hematologic malignancies and HCT in order to adopt best practices to improve patient outcomes and minimize harm of inappropriate antimicrobial use.
Target Audience
Physicians and Advanced Practice Providers, and other health care providers interested in the subject matter.
Learning Objectives
- Outline current recommendations for antimicrobial prophylaxis.
- Distinguish situations where antimicrobial prophylaxis is appropriate.
- Examine current evidence on antimicrobial stewardship in the patient population discussed.
- Discuss possible barriers and biases which may impact patient care (i.e., race, ethnicity, language, gender identity/orientation, age, socioeconomic status, attitudes, feelings, or other characteristics).
Virtual Meeting- Zoom
Monica Slavin, MBBS, MD Head of Department, Infectious Diseases; Director, National Center for Infections in Cancer; Professor and Chair, Infections in Cancer and Transplantation; University of Melbourne
Presenter: Dr. Slavin has indicated the following relevant financial relationships: Grant/Research Support from F2G, Gilead Sciences, Merck, and Pfizer; Consultant for Basilea, Elion Therapeutics, Gilead Sciences, and Roche.
Planner: Sanjeet Singh Dadwal, MD has indicated the following relevant financial relationships: Grant/Research Support from Ansun, F2G, Pfizer, Pulmotec; Consultant for Ansun, Karius, Merck; On the Speakers Bureau for Karius and Takeda.
The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.
CME Committee/Reviewer no relevant financial relationships: Daneng Li, MD
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1 Credit™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
Available Credit
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this 2025 Department of Medicine Grand Rounds | Antimicrobial Stewardship and Current Status of Antimicrobial Prophylaxis in Patients with Hematologic Malignancies and Hematopoietic Cell Transplantation for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity. - 1.00 Attendance